GO:0006695 cholesterol biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006695 cholesterol biosynthetic process describes the enzymatic reactions that convert acetyl-CoA into cholesterol, the principal sterol of vertebrates.
• The pathway is a multistep, energy-intensive process that requires NADPH and oxygen and is compartmentalized between the cytoplasm, endoplasmic reticulum, and peroxisomes.
• Key rate-limiting enzymes include HMGCR, MVK, and the post-squalene enzymes DHCR7 and DHCR24, which are frequent targets in disease and drug research.
• Dysregulation of cholesterol biosynthesis is linked to cancer, developmental disorders, and neurodegeneration, making it a major therapeutic focus.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of each enzymatic step and regulatory node.
• Quantitative methods such as cholesterol efflux assays, lipidomics, and RNA-seq are essential to validate pathway activity and gene function.
Description
Cholesterol is a sterol molecule that is essential for membrane integrity, lipid raft formation, and the synthesis of bile acids, steroid hormones, and vitamin D. The cholesterol biosynthetic process (GO:0006695) encompasses the entire set of chemical reactions and pathways that build cholesterol from simple precursors, primarily acetyl-CoA. This pathway is one of the most energetically expensive anabolic routes in mammalian cells and is tightly regulated at transcriptional, post-transcriptional, and post-translational levels. Researchers study GO:0006695 because its intermediates and end products influence cell proliferation, immune function, and neuronal health, and because mutations in pathway enzymes cause severe developmental and metabolic disorders. Understanding the molecular details of cholesterol biosynthesis is therefore central to both basic cell biology and translational medicine.
cholesterol biosynthetic process At A Glance
| GO ID | GO:0006695 |
|---|---|
| GO term | cholesterol biosynthetic process |
| Ontology | biological_process |
| Synonym | cholesterol anabolism; cholesterol biosynthesis; cholesterol formation; cholesterol synthesis |
| Major function | De novo synthesis of cholesterol from acetyl-CoA for membrane and steroid precursor supply |
| Key compartments | Cytoplasm, endoplasmic reticulum, peroxisomes |
| Rate-limiting enzymes | HMGCR, MVK, DHCR7, DHCR24 |
| Cofactors | NADPH, ATP, oxygen |
| Disease relevance | Cancer, developmental disorders, neurodegeneration, cardiovascular disease |
What Is GO:0006695?
The cholesterol biosynthetic process (GO:0006695) is defined as the chemical reactions and pathways resulting in the formation of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. In practical terms, it is the ordered enzymatic conversion of acetyl-CoA through the mevalonate pathway, squalene epoxidation, lanosterol cyclization, and a series of demethylation, reduction, and isomerization steps that ultimately yield cholesterol.
Why Is cholesterol biosynthetic process Important in Cell Biology?
Cholesterol biosynthesis is fundamental to cell physiology because cholesterol modulates membrane fluidity, organizes lipid rafts, and serves as the precursor for steroid hormones, bile acids, and vitamin D. The pathway also generates intermediates such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate that prenylate small GTPases, linking cholesterol synthesis to cell signaling and proliferation. Consequently, dysregulation of GO:0006695 contributes to cancer progression, immune dysfunction, and neurodegenerative disease, and the pathway is a validated target for statins, antifungals, and emerging anticancer agents.
• Provides cholesterol for membrane biogenesis and lipid raft signaling.
• Supplies precursors for bile acids, steroid hormones, and vitamin D.
• Generates isoprenoids that modify RAS and Rho GTPases.
• Supports rapid proliferation of cancer cells by sustaining sterol supply.
• Regulates dendritic cell function and antigen presentation.
• Mutations cause developmental syndromes such as Smith-Lemli-Opitz syndrome.
• Is a target of statins and other lipid-lowering therapeutics.
• Contributes to neurodegeneration when neuronal cholesterol synthesis is impaired.
• Influences immune cell activation and inflammatory responses.
• Serves as a model for studying feedback regulation of anabolic pathways.
What Happens During cholesterol biosynthetic process?
Mevalonate pathway: acetyl-CoA to mevalonate
In simple terms: The cell first converts acetyl-CoA into mevalonate, a committed building block for all sterols.
The pathway begins with the condensation of three acetyl-CoA molecules to form HMG-CoA, which is then reduced to mevalonate by HMG-CoA reductase (HMGCR), the rate-limiting enzyme of cholesterol biosynthesis. This step consumes NADPH and is the primary target of statin drugs. The reaction is tightly regulated by sterol-mediated feedback on HMGCR transcription and protein stability.
Mevalonate to squalene: isoprenoid intermediates
In simple terms: Mevalonate is converted into activated isoprene units that are assembled into squalene.
Mevalonate is phosphorylated and decarboxylated to yield isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), which are condensed to geranyl pyrophosphate and farnesyl pyrophosphate. Two farnesyl pyrophosphate molecules are joined by squalene synthase to form squalene, the first committed sterol intermediate. These isoprenoid intermediates also serve as substrates for protein prenylation, linking the pathway to GTPase signaling.
Squalene to lanosterol: cyclization
In simple terms: Squalene is oxidized and cyclized to form lanosterol, the first sterol in the pathway.
Squalene is epoxidized by squalene monooxygenase (SQLE) to 2,3-oxidosqualene, which is then cyclized by lanosterol synthase (LSS) to lanosterol. This cyclization is a key branch point because lanosterol can be converted into cholesterol or other sterols depending on cell type. SQLE is regulated by cholesterol availability and is a potential drug target.
Lanosterol to cholesterol: post-squalene modifications
In simple terms: Lanosterol undergoes a series of demethylations, reductions, and isomerizations to become cholesterol.
The conversion of lanosterol to cholesterol requires multiple enzymes including CYP51A1, TM7SF2, LBR, SC5D, DHCR7, and DHCR24, which remove methyl groups, reduce double bonds, and isomerize the sterol nucleus. Defects in these enzymes cause distinct sterol profiles and human disorders such as Smith-Lemli-Opitz syndrome (DHCR7 deficiency). The final product, cholesterol, is then distributed to membranes or esterified for storage.
Compartmentalization and transport
In simple terms: Different steps of cholesterol synthesis occur in different parts of the cell.
Early steps of the pathway occur in the cytoplasm and endoplasmic reticulum, while later post-squalene steps are associated with the endoplasmic reticulum and peroxisomes. Cholesterol is transported between organelles by vesicular and non-vesicular mechanisms, and excess cholesterol is esterified by SOAT enzymes for storage in lipid droplets. This compartmentalization allows separate regulation of intermediate pools and prevents toxic sterol accumulation.
Key Genes Involved in GO:0006695 cholesterol biosynthetic process
The following genes encode enzymes and regulators that carry out or control the cholesterol biosynthetic process (GO:0006695).
| Gene | Major Role | Research Relevance |
|---|---|---|
| HMGCR | Rate-limiting enzyme converting HMG-CoA to mevalonate | Target of statins; feedback regulation studies |
| MVK | Phosphorylates mevalonate in the early pathway | Mevalonate kinase deficiency models |
| PMVK | Phosphomevalonate kinase in isoprenoid synthesis | Pathway flux analysis |
| MVD | Decarboxylates mevalonate diphosphate to IPP | Metabolic engineering and inhibitor studies |
| FDPS | Synthesizes farnesyl pyrophosphate | Prenylation and cancer research |
| FDFT1 | Squalene synthase condensing farnesyl pyrophosphate | Squalene pathway regulation |
| SQLE | Epoxidizes squalene to 2,3-oxidosqualene | Post-squalene regulation and drug targeting |
| LSS | Cyclizes oxidosqualene to lanosterol | Sterol branch point studies |
| CYP51A1 | Demethylates lanosterol | Azole antifungal target; sterol profiling |
| TM7SF2 | Sterol reductase in post-squalene steps | Congenital disorder models |
| LBR | Lamin B receptor with sterol reductase activity | Nuclear envelope and sterol synthesis |
| MSMO1 | C-4 methylsterol oxidase | Sterol intermediate analysis |
| NSDHL | 3-beta-hydroxysteroid dehydrogenase in cholesterol synthesis | CHILD syndrome models |
| SC5D | Sterol C5-desaturase | Lathosterolosis research |
| DHCR7 | Reduces 7-dehydrocholesterol to cholesterol | Smith-Lemli-Opitz syndrome |
| DHCR24 | Reduces desmosterol to cholesterol | Desmosterolosis and neuroprotection |
| EBP | Emopamil binding protein, sterol isomerase | Chondrodysplasia punctata models |
How Is cholesterol biosynthetic process Regulated?
Cholesterol biosynthesis is regulated by a negative feedback loop centered on sterol regulatory element-binding proteins (SREBPs) and the SCAP-INSIG system, which sense endoplasmic reticulum cholesterol levels and control the transcription of HMGCR and other pathway genes. HMGCR protein stability is also controlled by sterol-induced degradation, and AMPK can phosphorylate and inhibit HMGCR under low-energy conditions. In addition, oxysterols and bile acids suppress pathway activity through liver X receptor (LXR) and farnesoid X receptor (FXR) signaling, integrating cholesterol synthesis with efflux and catabolism. This multilayered regulation ensures that cholesterol production matches cellular demand and prevents lipotoxicity.
cholesterol biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DHCR7 | Smith-Lemli-Opitz syndrome | CRISPR knockout or point-mutation in HEK293 or patient fibroblasts |
| DHCR24 | Desmosterolosis and neurodegeneration | Knockout neuronal cell lines and sterol profiling |
| HMGCR | Cancer proliferation and statin response | Overexpression and point-mutation models in cancer cell lines |
| SQLE | Tumor growth and sterol pathway flux | Knockout and inhibitor-treated organoids |
| SC5D | Lathosterolosis | Knock-in of patient variants in cell models |
Cancer and metabolic reprogramming
Many cancer cells upregulate cholesterol biosynthesis to support rapid proliferation and membrane synthesis, and high expression of HMGCR or SQLE is associated with poor prognosis in some tumors. The pathway also supplies isoprenoids for oncogenic GTPase signaling, making it a candidate for therapeutic intervention. Targeting cholesterol synthesis enzymes with statins or specific inhibitors has shown context-dependent anticancer effects in preclinical models.
Developmental and sterol biosynthesis disorders
Inherited defects in post-squalene enzymes cause a group of developmental disorders characterized by distinct sterol profiles, including Smith-Lemli-Opitz syndrome (DHCR7), desmosterolosis (DHCR24), and lathosterolosis (SC5D). These conditions highlight the importance of cholesterol biosynthesis for embryonic patterning, brain development, and skeletal formation. Diagnosis relies on gas chromatography-mass spectrometry of sterol intermediates, and experimental models often use patient-derived cells or CRISPR-engineered cell lines.
Neurodegeneration and brain cholesterol metabolism
The brain synthesizes its own cholesterol, and dysregulation of this pathway has been linked to neurodegenerative conditions such as Alzheimer disease and Huntington disease. Neuronal cholesterol synthesis is essential for synapse formation and membrane integrity, and its impairment can contribute to cognitive decline. Research models often use neuronal cell lines or iPSC-derived neurons with CRISPR-edited pathway genes to study these mechanisms.
Immune cell function and inflammation
Cholesterol biosynthesis influences dendritic cell maturation, antigen presentation, and inflammatory cytokine production. Modulating the pathway can alter immune responses, and statins have immunomodulatory effects partly through inhibition of HMGCR. Studying cholesterol synthesis in immune cells requires careful control of culture conditions and lipid availability.
From cholesterol biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of an enzyme block cholesterol synthesis? | CRISPR knockout cell line with lipidomics |
| Does a patient variant impair enzymatic activity? | Point-mutation knock-in cell line |
| Can a tagged enzyme be tracked in live cells? | Tagged knock-in with fluorescent protein |
| Does overexpression drive proliferation? | Stable overexpression in cancer cell lines |
| Which genes regulate pathway flux? | CRISPR library screening with sterol readout |
| How does cholesterol efflux change? | Quantitative efflux assay in edited cells |
How to Study the cholesterol biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS lipidomics | Cholesterol and intermediate sterol levels | Pathway activity and disease diagnosis |
| Cholesterol efflux assay | Movement of cholesterol to acceptors | Reverse cholesterol transport studies |
| RNA-seq | Transcript levels of pathway genes | Regulatory network analysis |
| Proteomics | Protein abundance and modifications | Enzyme stability and feedback |
| Fluorescence imaging | Subcellular localization of enzymes and sterols | Compartmentalization studies |
| CRISPR library screening | Gene essentiality and pathway dependencies | Target discovery |
| Sterol enzymatic assays | Catalytic activity of individual enzymes | Variant functional validation |
Lipidomics and sterol profiling
Mass spectrometry-based lipidomics quantifies cholesterol and its intermediates, providing a direct readout of pathway activity in cells and tissues. This approach is essential for validating CRISPR models and for diagnosing sterol biosynthesis disorders.
Cholesterol efflux and flux assays
Cholesterol efflux assays measure the movement of cholesterol from cells to extracellular acceptors such as HDL, reflecting pathway output and reverse transport capacity. These assays are widely used to study ABCA1 and other transporters in the context of cholesterol biosynthesis.
Transcriptomics and proteomics
RNA-seq and quantitative proteomics reveal how CRISPR perturbations alter the expression of cholesterol pathway genes and related regulatory networks. Integrating these datasets with pathway databases helps identify feedback mechanisms and off-target effects.
Imaging and subcellular localization
Fluorescence microscopy with tagged enzymes or sterol-binding probes visualizes the subcellular distribution of cholesterol synthesis machinery and lipid droplets. Live-cell imaging can track dynamic changes in endoplasmic reticulum and peroxisomal compartments.
How CRISPR Can Be Used to Study GO:0006695 cholesterol biosynthetic process
Knockout
CRISPR knockout of cholesterol biosynthesis genes such as HMGCR, SQLE, or DHCR7 creates isogenic cell lines to test pathway dependency and compensatory mechanisms. Knockout models are validated by sterol profiling and growth assays, and they are useful for identifying synthetic lethal interactions.
Point Mutation
Point-mutation knock-in allows precise modeling of patient variants in enzymes like DHCR7 or DHCR24, enabling functional assessment of catalytic activity and protein stability. These models are valuable for genotype-phenotype correlation and drug response studies.
Knock-in
Tagged knock-in of pathway enzymes with fluorescent or affinity tags supports live-cell imaging and proteomic interactome studies. Knock-in of reporter cassettes under endogenous promoters can monitor pathway gene expression in real time.
Overexpression
Overexpression of rate-limiting enzymes such as HMGCR or SQLE in cancer cell lines tests whether increased pathway flux promotes proliferation or drug resistance. Overexpression models are also used to study feedback regulation and lipid droplet formation.
How EDITGENE Supports cholesterol biosynthetic process Research
Researchers studying cholesterol biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in pathway regulation, disease progression, or drug response. Rigorous causal inference requires isogenic models that isolate the gene of interest from confounding background variation, and CRISPR-based editing provides the precision needed for such experiments.
Contact EDITGENE today to design your custom CRISPR model for cholesterol biosynthetic process research.
Frequently Asked Questions About cholesterol biosynthetic process
What is GO:0006695 cholesterol biosynthetic process?
GO:0006695 is the Gene Ontology term for the chemical reactions and pathways that produce cholesterol from acetyl-CoA, the principal sterol of vertebrates.
What genes are involved in cholesterol biosynthesis?
Key genes include HMGCR, MVK, FDPS, FDFT1, SQLE, LSS, CYP51A1, DHCR7, and DHCR24, among others.
What is the rate-limiting step of cholesterol synthesis?
The conversion of HMG-CoA to mevalonate by HMGCR is the rate-limiting and most regulated step.
How is cholesterol biosynthesis regulated?
It is regulated by SREBP-SCAP-INSIG feedback, HMGCR degradation, AMPK signaling, and oxysterol receptors such as LXR.
What diseases are linked to cholesterol biosynthesis defects?
Smith-Lemli-Opitz syndrome, desmosterolosis, lathosterolosis, cancer, and neurodegeneration are linked to pathway dysfunction.
How can I study cholesterol biosynthesis in the lab?
Common methods include lipidomics, cholesterol efflux assays, RNA-seq, proteomics, imaging, and CRISPR screening.
What is the role of DHCR7 in cholesterol synthesis?
DHCR7 catalyzes the final reduction of 7-dehydrocholesterol to cholesterol, and its deficiency causes Smith-Lemli-Opitz syndrome.
Can CRISPR be used to model cholesterol disorders?
Yes, CRISPR knockout and point-mutation knock-in models accurately reproduce patient variants and pathway defects.
Why is cholesterol biosynthesis important in cancer?
Cancer cells often upregulate the pathway to support proliferation and isoprenoid signaling, making it a therapeutic target.
What are the main intermediates of cholesterol biosynthesis?
Intermediates include mevalonate, farnesyl pyrophosphate, squalene, lanosterol, and desmosterol.
Conclusion
The cholesterol biosynthetic process (GO:0006695) is a central anabolic pathway that supplies cholesterol for membranes, steroid hormones, and bile acids while also generating signaling isoprenoids. Its dysregulation contributes to cancer, developmental disorders, and neurodegeneration, and it remains a major target for therapeutic intervention. CRISPR-based models and quantitative lipidomics now allow researchers to dissect each enzymatic step and regulatory node with unprecedented precision.
References
- 1. Schade DS et al.. 2020. Cholesterol Review: A Metabolically Important Molecule.. Endocr Pract 26(12):1514-1523 PMID: 33471744
- 2. Cui D et al.. 2025. Cholesterol metabolism: molecular mechanisms, biological functions, diseases, and therapeutic targets.. Mol Biomed 6(1):72 PMID: 41062796
- 3. Weis HJ. 1970. [Cholesterol metabolism].. Klin Wochenschr 48(20):1203-9 PMID: 4920502
- 5. Peeples ES et al.. 2024. Chemical Inhibition of Sterol Biosynthesis.. Biomolecules 14(4) PMID: 38672427
- 6. Meng Y et al.. 2021. Cholesterol metabolism and tumor.. Zhejiang Da Xue Xue Bao Yi Xue Ban 50(1):23-31 PMID: 34117857
- 7. You Z et al.. 2023. Lipid metabolism in dendritic cell biology.. Immunol Rev 317(1):137-151 PMID: 37172120
- 8. Robichaud S et al.. 2019. Quantifying Cellular Cholesterol Efflux.. Methods Mol Biol 1951:111-133 PMID: 30825148
